Loading...
Loading...
NRSNW| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 3,379.0K |
| Operating I/L | -3,379.0K |
| Other Income/Expense | 229.0K |
| Interest Income | -960.0K |
| Pretax | -3,150.0K |
| Income Tax Expense | -176.0K |
| Net Income/Loss | -2,974.0K |
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company based in Israel, specializing in the discovery and development of treatments for neurodegenerative diseases. The company's lead product candidate, PrimeC, is an oral formulation designed to address amyotrophic lateral sclerosis. Additionally, NeuroSense Therapeutics has a preclinical pipeline that includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease.
